Étiquette : psilocybine

Intensity of Mystical Experiences Occasioned by 5-MeO-DMT and Comparison With a Prior Psilocybin Study, Joseph Barsuglia et al., 2018

Intensity of Mystical Experiences Occasioned by 5-MeO-DMT and Comparison With a Prior Psilocybin Study Joseph Barsuglia, Alan K. Davis, Robert Palmer, Rafael Lancelotta, Austin-Marley Windham-Herman, Kristel Peterson, Martin Polanco, Robert Grant and Roland R. Griffiths Frontiers in Psychology, 2018, Vol 9, Article doi : 10.3389/fpsyg.2018.02459   5-MeO-DMT is a psychoactive substance found in high concentrations in the bufotoxin of the Colorado River Toad (Bufo alvarius). Emerging evidence suggests that vaporized 5-MeO-DMT may occasion mystical experiences of comparable intensity to those occasioned by more widely studied psychedelics such as psilocybin, but no empirical study has tested this hypothesis. Data was obtained from 20 individuals (Mage = [...]

Lire la suite

La médecine psychédélique renaît peu à peu, France Inter, L’invité de 6h20, vendredi 14 février 2020, sur le site du CIRC

L’invité de 6h20 – La médecine psychédélique renaît peu à peu Fév15 Revue de presse vendredi 14 février 2020 par Mathilde Munos Stéphanie Chayet, journaliste, auteure de Phantastica, ces substances interdites qui guérissent (Grasset) Stéphanie Chayet : “Il n’y a pas plus de troubles psychiatriques chez les usagers de drogues psychédéliques Après le cannabis thérapeutique, verra-t-on d’autres substances, aujourd’hui considérées comme des drogues, devenir des médicaments ? , nous en parlons avec la journaliste Stéphanie Chayet, auteure de « Phantastica ». Elle est l’invitée du 5/7.   https://www.circ-asso.net/linvite-de-6h20-la-medecine-psychedelique-renait-peu-a-peu/ Lecteur audio 00:00 00:00 Source : franceinter.fr Catégorie Revue de presse 15 février 2020

Lire la suite

Classic Hallucinogens and Mystical Experiences : Phenomenology and Neural Correlates, Frederick S. Barrett & Roland R. Griffiths, 2018

Classic Hallucinogens and Mystical Experiences : Phenomenology and Neural Correlates Frederick S. Barrett, Roland R. Griffiths Current Topics in Behavioral Neurosciences, 2018, 36, 393–430. doi : 10.1007/7854_2017_474   Abstract This chapter begins with a brief review of descriptions and definitions of mystical-type experiences and the historical connection between classic hallucinogens and mystical experiences. The chapter then explores the empirical literature on experiences with classic hallucinogens in which claims about mystical or religious experiences have been made. A psychometrically validated questionnaire is described for the reliable measurement of mystical-type experiences occasioned by classic hallucinogens. Controlled laboratory studies show that under double-blind conditions that provide significant controls for [...]

Lire la suite

Psychedelics and potential benefits in “healthy normals”: A review of the literature, Sam GANDY, 2019

Psychedelics and potential benefits in “healthy normals”: A review of the literature Sam GANDY Journal of Psychedelic Studies, 2019, 3, (3), 280–287. Doi : 10.1556/2054.2019.029   We are in the midst of a psychedelic research renaissance. With research examining the efficacy of psychedelics as a treatment for a range of mental health indications still in its early stages, there is an increasing body of research to show that careful use of psychedelics can yield a variety of benefits in “healthy normals” and so lead to “the betterment of well people.” Psychedelics have been found to modulate neuroplasticity, and usage in a supportive setting can result [...]

Lire la suite

A systematic study of microdosing psychedelics, Vince Polito & Richard J. Stevenson, 2019

A systematic study of microdosing psychedelics RESEARCH ARTICLE Vince Polito, Richard J. Stevenson PLoS ONE, 2019, 14, (2), e0211023. Doi : 10.1371/journal.pone.0211023   Abstract The phenomenon of ‘microdosing’, that is, regular ingestion of very small quantities of psychedelic substances, has seen a rapid explosion of popularity in recent years. Individuals who microdose report minimal acute effects from these substances yet claim a range of long-term general health and wellbeing benefits. There have been no published empirical studies of microdosing and the current legal and bureaucratic climate makes direct empirical investigation of the effects of psychedelics difficult. In Study One we conducted a systematic, observational investigation of individuals [...]

Lire la suite

Accounting for Microdosing Classic Psychedelics, Blake Beaton et al., 2019

Accounting for Microdosing Classic Psychedelics Blake Beaton, Heith Copes, Megan Webb, Andy Hochstetler, and Peter S. Hendricks Journal of Drug Issues, 2019, 1–12 Doi : 10.1177/0022042619871008   Abstract Microdosing classic psychedelics (e.g., LSD [lysergic acid diethylamide] and psilocybin) is the practice of taking small amounts of these substances to bring about various positive life changes. Little is known about the subjective experiences and perceptions of those who engage in the practice. Accordingly, we use the sociology of accounts as a theoretical framework to explore the ways that those who microdose excuse or justify their practice. Using data from semistructured interviews with 30 people who had microdosed, [...]

Lire la suite

A propos de : Voyage aux confins de l’esprit, de Michael Pollan, Dopamine, 13, 2020

A propos de : Voyage aux confins de l’esprit, de Michael Pollan (Ce que le LSD et la psilocybine nous apprennent sur nous-mêmes, la conscience, la mort, les addictions et la dépression) à propos de l'ouvrage de Michael Pollan Traduction : Leslie Talaga et Caroline Lee Editions Quanto, octobre 2019 444 pages - 23,25 euros Dans l'excellente Revue Dopamine, 2020, n°13, pp 59-69 Ce voyage aux confins de l’esprit de Michael Pollan, journaliste scientifique, nous embarque sur la planète psychédélique, celle où des substances comme le LSD ou les champignons psilocybes, par exemple, ont acquis du galon... Après avoir eu leurs heures de gloire dans les années [...]

Lire la suite

A Comparative Review of the Neuro- Psychopharmacology of Hallucinogen-Induced Altered States of Consciousness : The Uniqueness of Some Hallucinogens, Ümit Sayin, 2012

A Comparative Review of the Neuro- Psychopharmacology of Hallucinogen-Induced Altered States of Consciousness : The Uniqueness of Some Hallucinogens Ümit Sayin NeuroQuantology, June 2012, Volume 10, Issue 2,  316-340. eISSN 1303-5150   ABSTRACT Altered states of consciousness induced by hallucinogens (H-ASC) is still a vaguely understood phenomenon. Taken the diverse psychological effects they exert, the main mechanism of action of hallucinogens; LSD, ibogaine, THC, PCP, MDMA, methamphetamine, mescaline, psilocybin and DMT, of which psychological effects are discussed in the article, are not properly understood and explained by the modern methods of neuroscience due to the lack of vigorous research. The involvement of some receptors, such as, [...]

Lire la suite

Psilocybin Benefits in Cancer Sustained Nearly 5 Years Later, Nancy A. Melville, 2020

Psilocybin Benefits in Cancer Sustained Nearly 5 Years Later Nancy A. Melville Medscape, January 28, 2020 Medscape Medical News © 2020 Cancer patients who were treated with a one-time, single dose of the psychedelic drug psilocybin, combined with psychotherapy, showed significant benefits on measures of emotional and existential distress nearly 5 years after receiving the therapy, new research indicates. In addition to reporting improved well-being or life satisfaction, some patients rated the treatment as being "among the most personally meaningful and spiritually significant experiences of their lives," the authors note. The study, the longest-spanning evaluation to date of the effects of psilocybin in the treatment of cancer-related psychiatric distress, was [...]

Lire la suite